[REVISION HISTORY]

Humacyte clinical trial and financial updates

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-08-19 15:18 UTC → 2026-08-20 01:32 UTC · added ~~removed~~

Humacyte reported its second quarter 2026 financial results alongside positive interim data from its V012 Phase 3 trial. The trial, which utilized acellular tissue engineered vessels (ATEV) in female dialysis patients, demonstrated that ATEV outperformed AV fistula by providing an average of 91 more catheter-free days and lower infection rates. Following these results, the company intends to file a supplemental Biologics License Application (sBLA) for dialysis access with the FDA during the second half of 2026. Specifically, Humacyte now aims to submit this supplemental BLA in November 2026. Furthermore, the FDA has accepted an Investigational New Drug (IND) application for a Phase 2a study involving its coronary tissue engineered vessel (CTEV) for CABG, which is slated to begin in Q3 2026. Financially, Symvess sales increased to $0.4 million in Q2 2026 from $0.1 million the previous year. Despite a quarterly net loss of $36.8 million, Humacyte reported $80.3 million in cash and cash equivalents as of June 30, 2026, following a $57.5 million public equity offering. The company also anticipates achieving approximately $14.3 million in cost savings through restructuring during 2026.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.